Edition:
United States

Zoetis Inc (ZTS.N)

ZTS.N on New York Stock Exchange

71.07USD
22 Nov 2017
Change (% chg)

$-0.29 (-0.41%)
Prev Close
$71.36
Open
$71.33
Day's High
$71.76
Day's Low
$70.96
Volume
442,762
Avg. Vol
613,133
52-wk High
$72.14
52-wk Low
$48.55

Summary

Name Age Since Current Position

Michael McCallister

64 2015 Non-Executive Independent Chairman of the Board

Juan Alaix

65 2012 Chief Executive Officer, Director

Glenn David

46 2016 Chief Financial Officer, Executive Vice President

Roxanne Lagano

52 2012 Chief Human Resource Officer, Executive Vice President

Andrew Fenton

52 Executive Vice President, Chief Information Officer

Heidi Chen

50 2012 Executive Vice President, General Counsel, Corporate Secretary

Alejandro Bernal

44 2015 Executive Vice President, Group President - Strategy, Commercial and Business Development

Catherine Knupp

56 2012 Executive Vice President, President - Research and Development

Clinton Lewis

51 2015 Executive Vice President, President - International Operations

Kristin Peck

46 2015 Executive Vice President, President - U.S. Operations

Roman Trawicki

53 2015 Executive Vice President, President of Global Manufacturing and Supply

Linda Rhodes

66 2017 Director

Paul Bisaro

56 2015 Independent Director

Frank D'Amelio

59 2016 Independent Director

Sanjay Khosla

66 2013 Independent Director

Gregory Norden

59 2013 Independent Director

Louise Parent

66 2013 Independent Director

Willie Reed

62 2014 Independent Director

Robert Scully

67 2013 Independent Director

William Steere

80 2013 Independent Director

Biographies

Name Description

Michael McCallister

Mr. Michael B. McCallister is the Non-Executive Independent Chairman of the Board of Zoetis Inc. from 2010 to 2013. Humana is a health care company that offers a wide range of insurance products and health and welfare services. Mr. McCallister joined Humana in 1974, and was its Chief Executive Officer from February 2000 until his retirement on December 31, 2012. During his tenure as CEO, Humana gained a reputation as one of the industry’s leading people-focused innovative companies, leveraging products, processes and technology to help individuals take control of their own health. Mr. McCallister served for many years on the board of the Business Roundtable and is past Chairman of its Health and Retirement Task Force. He is currently on the boards of AT&T, where he serves on the audit committee, Fifth Third Bank and Bellarmine University. Mr. McCallister holds a bachelor’s degree in accounting from Louisiana Tech University and an MBA from Pepperdine University.

Juan Alaix

Mr. Juan Ramon Alaix is the Chief Executive Officer and Director of Zoetis Inc. From 2006 to 2012 he served as President of Pfizer Animal Health, and was responsible for its overall strategic direction and financial performance. Under his leadership, the company grew to become a $4.3 billion enterprise in 2012. Mr. Alaix has more than 35 years’ experience in finance and management, including 20 years in the pharmaceutical industry. He joined Pfizer in 2003 and held various positions, including Regional President of Central/Southern Europe for Pfizer’s pharmaceutical business. Prior to that, Mr. Alaix held various positions with Pharmacia, including as Country President of Spain, from 1998 until Pharmacia’s acquisition by Pfizer in 2003. Earlier in his career he served in general management with Rhône-Poulenc Rorer in Spain and Belgium. In 2013, Mr. Alaix completed a two-year term as President of the International Federation for Animal Health (“IFAH”), now known as HealthforAnimals, and he continues to serve as a member of its board and executive committee. HealthforAnimals represents manufacturers of veterinary medicines, vaccines and other animal health products in both developed and emerging markets. A native of Spain, Mr. Alaix received a graduate degree in economics from the Universidad de Madrid.

Glenn David

Mr. Glenn David serves as Chief Financial Officer and Executive Vice President of the Company. Before the Zoetis IPO, David served in various financial roles at Pfizer, including vice president of Global Finance for Pfizer Animal Health and vice president of Finance for the U.S. Primary Care franchise. David also played important financial roles in Pfizer’s integration of the Pharmacia, Wyeth and King Pharmaceuticals’ acquisitions. Prior to joining Pfizer in 1999, David gained valuable financial experience at Bankers Trust, Paine Webber and Credit Suisse. David graduated magna cum laude with a bachelor’s degree in Finance from Binghamton University, and earned his MBA in Finance/Information Technology from New York University.

Roxanne Lagano

Ms. Roxanne Lagano is the Chief Human Resource Officer and Executive Vice President of Zoetis Inc. In this role, she is responsible for the company's worldwide human resources management. In 2015, Roxanne was also given responsibility for the corporate communications function. Prior to joining Zoetis, Ms. Lagano was senior vice president, Global Compensation, Benefits and Wellness for Pfizer. In that role, Ms. Lagano was responsible for the design and implementation of Pfizer's compensation and employee benefit programs around the globe. She was also responsible for Pfizer's wellness strategies, including the Healthy Pfizer program, and for the human resources aspects of the company's merger, acquisition and divestiture activities. Ms. Lagano joined Pfizer in 1997 as manager, Tax Planning after specializing in employee benefits, executive compensation and mergers and acquisitions at Schulte, Roth and Zabel, LLP, a New York law firm. After joining Pfizer's legal division in 1999, Ms. Lagano joined Pfizer's Human Resources organization in 2000. During her time in HR for Pfizer, Ms. Lagano held various positions of increasing responsibility, including senior director of business transactions (HR) and senior director, employee benefits. Ms. Lagano holds a Juris Doctor degree from Hofstra University School of Law and a Bachelor of Science degree from Long Island University.

Andrew Fenton

Mr. Andrew Fenton is the Executive Vice President and Chief Information Officer of the Company. In this role, he is responsible for leading a global Information Technology Services (ITS) team that supports the business performance, efficiency and customer experiences for this $4.8 billion company. With more than 25 years of experience in life sciences and information technology, Andrew has held several positions in the pharmaceutical industry, with increasing responsibility for planning and IT infrastructure to support manufacturing plants and large-scale technology transformation programs, including SAP. Prior to joining Zoetis in 2014, Andrew was a partner and principal with EY in the Life Sciences practice supporting CIO Transformation Services. Previously he was Senior Vice President and CIO of Warner Chilcott, where he was instrumental in building an IT organization and driving shareholder value. He also held senior positions at IBM Global Services and at PricewaterhouseCoopers in the Pharmaceutical Practice. Andrew graduated from BCIT - British Columbia in Canada, with a focus on Operations Management and Information Technology.

Heidi Chen

Ms. Heidi C. Chen serves as Executive Vice President, General Counsel, Corporate Secretary of Zoetis Inc. In this role, she is responsible for Zoetis' worldwide legal affairs, compliance and global security. Prior to Zoetis, Heidi was a Vice President and Assistant General Counsel, Pfizer Inc. and Chief Counsel, Pfizer Animal Health. Heidi joined Pfizer in 1998 and held numerous legal positions of increasing responsibility, including lead counsel for Pfizer’s Established Products (generics) business. Before Pfizer, Ms. Chen was in private practice at Clifford Chance in intellectual property and at Hughes Hubbard & Reed in litigation. She serves on the board of AALDEF, the Asian American Legal Education and Defense Fund. Ms. Chen earned a Bachelor’s degree from Yale University and received a Juris Doctorate from Cornell Law School. She has participated in Columbia Business School’s Executive Education Program.

Alejandro Bernal

Mr. Alejandro Bernal is Executive Vice President, Group President - Strategy, Commercial and Business Development of Zoetis Inc. From October 2012 through April 2015 he served as our Executive Vice President and Area President of the Europe, Africa and Middle East region. He was Area President of the Europe, Africa and Middle East region for Pfizer’s animal health business unit from 2010 to 2012. Mr. Bernal joined Pfizer in 2000 and held various positions, including Area President of the Canada and Latin America region; Regional Director of Southwest and Central Latin America; Division Director for Central America and Colombia; Swine and Poultry Team Leader for Mexico; and Swine Product Manager for Northern Latin America for Pfizer Animal Health. Alejandro holds a doctorate in veterinary medicine from Universidad de Caldas (Colombia), a master's degree in physiology from Texas A&M University (USA), and a Master of Business Administration from Universidad de los Andes (Colombia) and Manchester Business School (UK).

Catherine Knupp

Dr. Catherine A. Knupp is the Executive Vice President, President - Research and Development of Zoetis Inc. Prior to that, Dr. Knupp served as vice president, Veterinary Medicine Research and Development at Pfizer Animal Health, a position she held since 2005. In her role, she is responsible for managing global R&D activities in support of discovering and registering medicines and vaccines to prevent disease in companion animals and livestock species, and improve health and optimize performance. Prior to joining Pfizer Animal Health, Dr. Knupp led Pfizer's Michigan laboratories in pharmacokinetics, dynamics and metabolism, and chaired the Midwest Exploratory Development Management Team in Pfizer Global Research and Development. She began her career in 1987 at Bristol-Myers Squibb where she held positions of increasing responsibility in drug metabolism and pharmacokinetics. This experience led to her appointment as executive director, Drug Metabolism and Pharmacokinetics. Her last position with that company was as vice president, Chemical Manufacturing Controls (CMC), where she was responsible for global CMC regulatory submissions. Dr. Knupp earned her Doctor of Veterinary Medicine (DVM) degree in 1985 from the University of Illinois, where she also received a master's degree in toxicology and a bachelor's degree in veterinary biosciences. She also earned another bachelor's degree in chemistry from Western Illinois University.

Clinton Lewis

Mr. Clinton A. Lewis, Jr. is Executive Vice President, President - International Operations of the Company. In this role, he oversees the management of the livestock and companion animal business markets outside the United States. Mr. Lewis previously served as president, U.S. Operations at Zoetis and in the Pfizer Animal Health organization. He joined Pfizer Animal Health in 2007. Mr. Lewis joined Pfizer in 1988 as a sales representative in Long Island, N.Y., and has held positions of increasing responsibility in several areas across various commercial operations dedicated to human health prior to joining animal health, including vice president and general manager of Pfizer's U.S. Anti-Infectives/HIV business unit. In 2011, Mr. Lewis was elected chairman of the Animal Health Institute (AHI) for the 2011-12 term. A member of AHI since 2007, Mr. Lewis previously served as AHI vice chair for the 2009-2010 term. AHI is the trade association for the animal health industry in the U.S. advocating on various issues important to the industry, including efficient and effective regulatory and approval processes by the U.S. Department of Agriculture (USDA), the Food and Drug Administration (FDA), and the Environmental Protection Agency (EPA). Mr. Lewis holds a bachelor's degree in biology from Fairfield University and a Master of Business Administration in marketing from Fairleigh Dickinson University.

Kristin Peck

Ms. Kristin C. Peck is the Executive Vice President, President - United States Operations of the Company. In this role, she oversees the management of the livestock and companion animal businesses in the United States. Previously, Ms. Peck was group president at Zoetis. In this role, she was responsible for Global Manufacturing and Supply, Global Poultry, Global Diagnostics, Corporate Development and New Product Marketing and Global Market Research. In this role she led the Zoetis Supply Network Strategy, the Zoetis Digital Strategy and the acquisition of Abbott Animal Health. Ms. Peck is a member of the Advisory Board for the Deming Center for Quality, Productivity and Competitiveness at Columbia Business School. Before joining Zoetis, Ms. Peck served as executive vice president, Worldwide Business Development and Innovation at Pfizer Inc. and as a member of Pfizer's Executive Leadership Team. In this role, she was responsible for Pfizer's merger and acquisition, licensing, venture capital, alliance management and innovative business model activities. She was also responsible for the evaluation of strategic alternatives for Pfizer's Animal Health and Nutrition businesses. Prior to joining Pfizer, Ms. Peck focused on strategy and merger-related issues in the pharmaceutical and financial services industries at the Boston Consulting Group (BCG). She began her career in private equity and real estate finance at The Prudential Realty Group, The O'Connor Group and J.P. Morgan. Ms. Peck is a member of the Thomson Reuters’ Board of Directors and serves on the Human Resources Committee. In addition, she is a member of the Advisory Board for the Deming Center for Quality, Productivity and Competitiveness at Columbia Business School. Ms. Peck holds a Bachelor's degree from Georgetown University and a Master of Business Administration from Columbia Business School.

Roman Trawicki

Mr. Roman Trawicki is Executive Vice President, President of Global Manufacturing and Supply of the Company. He joined Zoetis in January 2015 as President, Global Manufacturing and Supply. From 2009 to 2014, he was GE Healthcare’s General Manager of Global Supply Chain for Medical Diagnostics, where he focused on diagnostics, injectable contrast media and nuclear medicines. Mr. Trawicki earned his bachelor's degree in Mechanical Engineering from University of Hertfordshire, U.K. in 1986, and worked in engineering roles for Ford Motor Company, Black and Decker Corporation and Cummins Engine Company before moving into the healthcare sector at Smith and Nephew in 1992.

Linda Rhodes

Dr. Linda Rhodes is Director of the Company. Dr. Rhodes has extensive experience as a research scientist, academic, veterinary practitioner and business leader, spanning nearly 30 years across the animal health industry. Dr. Rhodes most recently served as the Chief Scientific Officer of Aratana Therapeutics, a publicly traded animal health company, from 2012 to 2016, and she had also served as Chief Executive Officer of Aratana from 2011 to 2012. She is a founder of AlcheraBio, LLC, a veterinary contract research organization, and held research and development positions at Merial, Merck & Company, and Sterling-Winthrop Drug Company. Dr. Rhodes also held several teaching positions and worked as a bovine veterinarian in private practice for many years. Dr. Rhodes earned her Ph.D. in Physiology from Cornell University and her V.M.D. from the University of Pennsylvania. She is currently an adjunct professor for the Graduate School of Animal Science at Rutgers University and a member of the Board of Directors of ImmuCell Corporation, a publicly traded animal health company.

Paul Bisaro

Mr. Paul M. Bisaro is an Independent Director of the Company. Mr. Bisaro was the Executive Chairman of the board of directors of Allergan plc (formerly Actavis plc) from July 2014 to October 2016. Until June 2014, Mr. Bisaro served as Board Chairman, President and Chief Executive Officer of Actavis (formerly Watson Pharmaceuticals). He was appointed President, Chief Executive Officer and a member of the board of Watson Pharmaceuticals in September 2007; and later appointed Chairman of the board of Watson Pharmaceuticals in October 2013. Prior to joining Watson, Mr. Bisaro was President, Chief Operating Officer and a member of the board of Barr Pharmaceuticals, Inc., a global specialty pharmaceutical company, from 1999 to 2007. Between 1992 and 1999, Mr. Bisaro served as General Counsel of Barr, and from 1997 to 1999 served in various additional capacities including Senior Vice President – Strategic Business Development. Prior to joining Barr, Mr. Bisaro was associated with the law firm Winston & Strawn and a predecessor firm, Bishop, Cook, Purcell and Reynolds from 1989 to 1992. Mr. Bisaro currently serves on the board of directors of Allergan plc, Impax Laboratories and Zimmer Biomet Holdings, Inc., a world leader in musculoskeletal health solutions, and on the Board of Visitors of The Catholic University of America’s Columbus School of Law. Mr. Bisaro holds an undergraduate degree in General Studies from the University of Michigan and a Juris Doctor from The Catholic University of America in Washington, D.C.

Frank D'Amelio

Mr. Frank A. D'Amelio is an Independent Director of the Company. Mr. D’Amelio joined Pfizer in September 2007 and held various positions, including Senior Vice President and Chief Financial Officer. From November 2006 to August 2007, Mr. D’Amelio held the position of Senior Executive Vice President of Integration and Chief Administrative Officer at Alcatel-Lucent, S.A., a global telecommunications equipment company. Prior to the merger of Alcatel and Lucent Technologies in 2006, Mr. D’Amelio was the Chief Operating Officer of Lucent Technologies, responsible for leading business operations, including sales, the product groups, the services business, the supply chain, information technology operations, human resources and labor relations. In 2001, he was appointed Executive Vice President, Administration and Chief Financial Officer of Lucent, where he helped lead the company through one of the most challenging periods in the telecom industry’s history and returned the company to profitability. In this role, Mr. D’Amelio was responsible for management and oversight of all financial, accounting, real estate and labor relations operations and the operational aspects of the legal and human resources organizations. Mr. D’Amelio currently serves as a member of the board of Humana Inc., a health care company that offers a wide range of insurance products and health and welfare services, and as chair of its audit committee. He also serves on the board of the Independent College Fund of New Jersey, and formerly served as a member of the National Advisory Board of JPMorgan Chase & Co. Mr. D’Amelio earned his MBA in Finance from St. John’s University and his bachelor’s degree in Accounting from St. Peter’s College.

Sanjay Khosla

Mr. Sanjay Khosla is an Independent Director of the Company. Mr. Khosla is Former Executive Vice President of Mondelez International. Mr. Khosla was President, Kraft Foods, Developing Markets (now Mondelez International) from 2007 to 2013, Mr. Khosla transformed the $5 billion business into a $16 billion business, while significantly improving profitability. He also has animal health experience from his three-year tenure from 2004 to 2007 as Managing Director of Fonterra Brands and Food Service, a multinational dairy cooperative based in New Zealand. Mr. Khosla serves on the board of NIIT, Ltd., a company involved in technology-related educational services, and Iconix Brand Group, Inc., a company that licenses and markets a portfolio of consumer brands. From October 2008 until June 2015, he served on the board of Best Buy, Inc., a specialty retailer of consumer electronics, personal computers, entertainment software and appliances. Mr. Khosla holds a bachelor’s degree in electrical engineering from the Indian Institute of Technology in New Delhi. Mr. Khosla also completed the Advance Management Program at Harvard Business School. Mr. Khosla is currently a senior fellow and adjunct professor at the Kellogg School of Management, Northwestern University.

Gregory Norden

Mr. Gregory Norden is an Independent Director of the Company. Prior to his role as Chief Financial Officer of Wyeth, Mr. Norden held various senior positions with Wyeth Pharmaceuticals and American Home Products. Prior to his affiliation with Wyeth, Mr. Norden served as Audit Manager at Arthur Andersen & Co. Mr. Norden currently serves on the boards of NanoString Technologies, a provider of life science tools for translational research and development of molecular diagnostic products; Royalty Pharma, a leader in the acquisition of revenue-producing intellectual property; and Univision, the leading media company serving Hispanic America. Mr. Norden is a former director of Welch Allyn, where he served until 2015; Lumara Health, where he served until 2014; and Human Genome Sciences, Inc., where he served until 2012. In addition, Mr. Norden is the Managing Director of G9 Capital Group LLC, which invests in early stage ventures and provides corporate finance advisory services.

Louise Parent

Ms. Louise M. Parent is an Independent Director of the Company. Since early 2014, Ms. Parent has served as Of Counsel at the law firm of Cleary Gottlieb Steen & Hamilton LLP. Ms. Parent brings deep experience in corporate governance and board matters, and in compliance and risk management, gained during her tenure with American Express, where she worked extensively with the Audit, Compensation and Nomination and Governance committees in her role as General Counsel. Ms. Parent also served on the operating committee and global management team of American Express from 2003 through 2013 and was a member of the board of American Express Centurion Bank through 2013. Ms. Parent currently serves on the Supervisory Board of Deutsche Bank AG. Ms. Parent holds a bachelor’s degree from Smith College and a law degree from Georgetown University Law Center.

Willie Reed

Dr. Willie M. Reed is an Independent Director of the Company. Dr. Reed is Dean of the College of Veterinary Medicine at Purdue University since 2007. Dr. Reed has more than 30 years of experience in animal health and veterinary medicine, gained during his tenure at Purdue University and Michigan State University, and as a Diplomate of the American College of Veterinary Pathologists and Charter Diplomate of the American College of Poultry Veterinarians. Dr. Reed has served as President of the Association of American Veterinary Medical Colleges, President of the American Association of Veterinary Laboratory Diagnosticians, President of the American Association of Avian Pathologists and Chair of the American Veterinary Medical Association Council on Research. He currently serves on the American Veterinary Medical Association’s Member Services Committee. Dr. Reed has a Doctor of Veterinary Medicine degree from Tuskegee University, and a Ph.D. in Veterinary Pathology from Purdue University.

Robert Scully

Mr. Robert W. Scully is an Independent Director of the Company. He served as a member of the Office of the Chairman of Morgan Stanley from 2007 until his retirement in January 2009, where he had previously been Co-President of the firm, Chairman of global capital markets and Vice Chairman of investment banking. Prior to joining Morgan Stanley in 1996, he served as a Managing Director at Lehman Brothers and at Salomon Brothers Inc. He currently serves on the boards of KKR & Co. LP, a private equity and asset management firm, and Chubb Limited (formerly ACE Limited), a global property and casualty company. Previously, he served as a director of Bank of America Corporation, GMAC Financial Services and MSCI Inc. and as a Public Governor of FINRA, the Financial Industry Regulatory Authority. Mr. Scully holds a bachelor’s degree from Princeton University and an MBA from Harvard Business School.

William Steere

Mr. William C. Steere, Jr. is an Independent Director of the Company. Mr. Steere joined Pfizer in 1959 and held various positions, including Chief Executive Officer from 1991 until 2000, Chairman of the board of directors from 1992 until 2001, and member of the board of directors until 2011. Mr. Steere also served on the boards of Dow Jones & Company, Inc. until 2007, MetLife, Inc. until 2010 and Health Management Associates, Inc. until 2014.

Basic Compensation